

29 September 2025

STRICTLY PRIVATE AND CONFIDENTIAL

The Board of Directors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Room 1917, 19th floor, Lee Garden One
33 Hysan Avenue, Causeway Bay
Hong Kong

Dear Sirs,

Re: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Stock code: 2196) (the Company, together with its subsidiaries, the “Group”)

Discloseable and continuing connected transactions in relation to the renewal of financial services agreement

We refer to the circular of the Company dated 29 September 2025 (the “**Circular**”) in relation to the captioned letter. Capitalised terms used herein shall have the same meanings as those defined in the Circular, unless the context requires otherwise.

We confirm that: (i) as at the Latest Practicable Date, we did not have any direct or indirect interest in any assets which had been acquired, disposed of by, or leased to any member of the Group, or was proposed to be acquired, or disposed of by, or leased to any member of the Group, since 31 December 2024, being the date to which the latest audited financial statements of the Group were made up; and (ii) as at the Latest Practicable Date, we were not beneficially interested in the share capital of any member of the Group and did not have any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group.

We hereby give our written consent and confirm that we have not withdrawn our consent to the issue of the circular with the inclusion of our letter of advice to the Independent Board Committee and the Independent Shareholders (the “**Letter of Advice**”) and/or references to our name in the form and context in which they respectively appear in the Circular.

We confirm that the Letter of Advice was given as of the date stated therein for incorporation into the Circular. We also consent to this letter and the Letter of Advice being made available for documents on display as described in the appendix to the Circular.

Yours faithfully,
For and on behalf of
Yue Xiu Capital Limited



Cedric Wu
Associate Director